"Total net revenue, including product sales as well as the earnings contribution from Benicar, authorized generic sales of Lexapro, interest income and other income, is now expected to be $3.2 billion compared with the previous estimate of $3.4 billion.Analysts estimate full year earnings per share of $0.66 and revenue of $3.26 billion.In June, the company had expected GAAP earnings of $0.65 to $0." . . . .